Download PDF

1. Company Snapshot

1.a. Company Description

Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases.It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus.The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA.


It also has a manufacturing agreement with Samsung Biologics Co.,Ltd.for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc.for chronic hepatitis B virus.


Vir Biotechnology, Inc.was incorporated in 2016 and is headquartered in San Francisco, California.

Show Full description

1.b. Last Insights on VIR

Vir Biotechnology's recent performance was negatively impacted by its Q3 2025 earnings miss, with a quarterly loss of $1.17 per share versus the Zacks Consensus Estimate of a loss of $0.7. The company's revenue also missed estimates. Despite this, the stock has a consensus rating of "Moderate Buy" from 11 analysts, with 9 issuing a buy recommendation. Additionally, the company's CEO, Marianne De Backer, presented at the 44th Annual J.P. Morgan Healthcare Conference, and the company provided updates on its chronic hepatitis delta and oncology programs.

1.c. Company Highlights

2. Vir Biotechnology's Strategic Collaboration and Positive Phase I Data Drive Financial Performance

The company's financial performance for 2025 showed a net loss of $438 million, with cash, cash equivalents, and investments totaling $782 million as of year-end 2025. The actual EPS came out at -$0.31, beating estimates of -$0.42. Revenue growth is expected to be -18.7% next year. The company's financial position remains strong, with a cash runway extending into the second quarter of 2028.

Publication Date: Mar -03

📋 Highlights
  • Strategic Astellas Collaboration:: $1.7B total potential in upfront and milestone payments, with U.S. profits split 50-50 and ex-U.S. royalties tiered double-digits.
  • Phase I Efficacy Data:: 45% objective response rate in 11 evaluable patients (5 confirmed responses) at doses ≥3,000 mcg/kg, with durable PSA declines and radiographic responses.
  • Safety Profile:: No dose-limiting toxicities, 12% Grade 3+ adverse events (mostly lab abnormalities), and low-grade cytokine release syndrome in high-dose cohorts.
  • Financial Position:: $782M cash runway through Q2 2028, $438M 2025 net loss, and $335M upfront payment from Astellas to reduce near-term R&D spend.

Financial Highlights

The company's financial results were impacted by the strategic collaboration with Astellas, which provides immediate capital and significantly reduces near-term development spend while preserving substantial long-term economic upside. The total potential in combined upfront and milestone payments is $1.7 billion.

VIR-5500 Phase I Data

The Phase I data for VIR-5500 showed a compelling emerging safety and efficacy profile, with a favorable safety and tolerability profile and no observed dose-limiting toxicities. The data showed a clear dose response relationship for efficacy, with deep and consistent PSA declines at Q3 week doses at or above 3,000 micrograms per kilogram. As Mark Eisner stated, "we are very encouraged by the RECIST responses, particularly those occurring up to 27 weeks, and the concordance of RECIST responses with PSMA PET responses and deep PSA responses."

Valuation Metrics

The company's valuation metrics indicate a P/E Ratio of -2.97, P/B Ratio of 1.7, and P/S Ratio of 18.95. The EV/EBITDA is -2.77, and the Free Cash Flow Yield is -30.15%. These metrics suggest that the market is pricing in significant growth expectations, but the company's current financial performance and cash position may not support these expectations.

Collaboration with Astellas

The collaboration with Astellas provides significant financial benefits, including a $315 million upfront payment and up to $1.37 billion in development, regulatory, and ex-U.S. commercial milestones. The partnership will help accelerate the VIR-5500 program and divert expenses to other programs, as stated by Marianne De Backer, "the partnership with Astellas helps accelerate the VIR-5500 program and divert expenses to other programs."

Future Plans

The company plans to initiate late-line mCRPC expansion cohorts in the second quarter of 2026 and continue dose optimization in parallel to satisfy the FDA's requirements. The company also expects to enter Phase III in 2027 and is well-positioned due to the collaboration with Astellas. The go-forward dose has been selected in the 3,000 to 3,500 maintenance dose range, with a compelling dose response across all doses above 3,000 micrograms per kilogram.

3. NewsRoom

Card image cap

Vir Biotechnology to Participate in Upcoming Investor Conferences

Feb -26

Source: businesswire.com

Card image cap

Vir Biotechnology Announces Proposed Public Offering of Common Stock

Feb -24

Source: businesswire.com

Card image cap

Vir Biotechnology: Up On Prostate Data And Astellas Deal - I'm (Long-Term) Bullish

Feb -24

Source: seekingalpha.com

Card image cap

These Analysts Boost Their Forecasts On Vir Biotechnology

Feb -24

Source: benzinga.com

Card image cap

Stock Market Today: Dow Jones, Nasdaq 100 Futures Gain Amid AI-Led Sell-Off, Trump's Threat To Trading Partners—Whirlpool, Uber, HP In Focus

Feb -24

Source: benzinga.com

Card image cap

What's Happening With VIR Stock?

Feb -24

Source: forbes.com

Card image cap

Vir Biotechnology, Inc. (VIR) Q4 2025 Earnings Call Transcript

Feb -24

Source: seekingalpha.com

Card image cap

Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Beats Revenue Estimates

Feb -24

Source: zacks.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (9.95%)

6. Segments

Antibody-based Therapies

Expected Growth: 9.95%

Vir Biotechnology's antibody-based therapies exhibit strong growth driven by increasing demand for effective treatments of infectious diseases, strategic partnerships, and a robust pipeline of novel candidates. The company's focus on addressing high-unmet medical needs, coupled with its expertise in antibody discovery and development, fuels growth. Additionally, the rising prevalence of diseases such as hepatitis B and COVID-19 contributes to the segment's 9.95% growth.

7. Detailed Products

Sotrovimab

A monoclonal antibody for the treatment of COVID-19

VIR-3434

An HBV-neutralizing monoclonal antibody for the treatment of Hepatitis B

VIR-2218

A small interfering RNA (siRNA) for the treatment of Hepatitis B

VIR-2482

A monoclonal antibody for the treatment of Influenza A

VIR-3431

A monoclonal antibody for the treatment of HIV

8. Vir Biotechnology, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

The threat of substitutes for Vir Biotechnology, Inc. is medium due to the presence of alternative treatments and therapies for infectious diseases. While the company's products may have some unique features, they are not entirely irreplaceable.

Bargaining Power Of Customers

The bargaining power of customers is low for Vir Biotechnology, Inc. as the company's products are primarily sold to healthcare providers and governments, which have limited negotiating power.

Bargaining Power Of Suppliers

The bargaining power of suppliers is medium for Vir Biotechnology, Inc. as the company relies on a few key suppliers for raw materials and manufacturing services. While the company has some negotiating power, suppliers may still have some leverage.

Threat Of New Entrants

The threat of new entrants is high for Vir Biotechnology, Inc. as the biotechnology industry is highly competitive and attractive to new entrants. The company's intellectual property and regulatory approvals may provide some barriers to entry, but new entrants may still be able to enter the market.

Intensity Of Rivalry

The intensity of rivalry is high for Vir Biotechnology, Inc. as the company operates in a highly competitive industry with many established players. The company must continually innovate and differentiate its products to maintain market share.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 7.26%
Debt Cost 3.95%
Equity Weight 92.74%
Equity Cost 6.24%
WACC 6.07%
Leverage 7.83%

11. Quality Control: Vir Biotechnology, Inc. passed 4 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
OncoCyte

A-Score: 4.7/10

Value: 7.1

Growth: 5.9

Quality: 3.1

Yield: 0.0

Momentum: 8.0

Volatility: 4.3

1-Year Total Return ->

View Full Report
Stock-Card
2seventy bio

A-Score: 4.3/10

Value: 7.7

Growth: 4.4

Quality: 4.6

Yield: 0.0

Momentum: 8.5

Volatility: 0.7

1-Year Total Return ->

View Full Report
Stock-Card
Seer

A-Score: 4.1/10

Value: 8.2

Growth: 4.2

Quality: 4.5

Yield: 0.0

Momentum: 3.5

Volatility: 4.3

1-Year Total Return ->

View Full Report
Stock-Card
Curis

A-Score: 3.6/10

Value: 9.4

Growth: 3.8

Quality: 5.9

Yield: 0.0

Momentum: 1.5

Volatility: 1.3

1-Year Total Return ->

View Full Report
Stock-Card
Vir Biotechnology

A-Score: 3.3/10

Value: 7.8

Growth: 3.6

Quality: 5.0

Yield: 0.0

Momentum: 2.0

Volatility: 1.3

1-Year Total Return ->

View Full Report
Stock-Card
Pliant Therapeutics

A-Score: 2.6/10

Value: 8.0

Growth: 3.1

Quality: 3.5

Yield: 0.0

Momentum: 0.0

Volatility: 1.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

9.33$

Current Price

9.33$

Potential

-0.00%

Expected Cash-Flows